$TCRT
Alaunos Therapeutics, Inc.

2013 Q3 Form 10-Q Financial Statement

#000119312513326769 Filed on August 08, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.070M $3.720M $4.900M
YoY Change -46.23% -24.08% 25.0%
% of Gross Profit
Research & Development $6.247M $14.78M $18.26M
YoY Change -61.47% -19.1% 100.04%
% of Gross Profit
Depreciation & Amortization $180.0K $200.0K $150.0K
YoY Change -10.0% 33.33% 150.0%
% of Gross Profit
Operating Expenses $6.247M $14.78M $18.26M
YoY Change -61.47% -19.1% 39.95%
Operating Profit -$9.115M -$18.30M -$22.97M
YoY Change -58.05% -20.33% 78.75%
Interest Expense -$7.410M -$400.0K -$650.0K
YoY Change -287.59% -38.46% -130.66%
% of Operating Profit
Other Income/Expense, Net -$191.0K $7.000K $3.000K
YoY Change 354.76% 133.33% -70.0%
Pretax Income -$16.71M -$18.69M -$23.61M
YoY Change -6.23% -20.84% 120.24%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$16.71M -$18.69M -$23.61M
YoY Change -6.23% -20.84% 120.19%
Net Earnings / Revenue -8356.5% -9346.0% -11806.5%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.20 -$0.22 -$0.30
COMMON SHARES
Basic Shares Outstanding 83.52M shares 83.56M shares 79.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.60M $38.90M $110.4M
YoY Change -75.24% -64.76% -15.27%
Cash & Equivalents $23.63M $38.93M $110.4M
Short-Term Investments
Other Short-Term Assets $3.200M $4.100M $9.100M
YoY Change -55.56% -54.95% 810.0%
Inventory
Prepaid Expenses
Receivables $400.0K $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $27.28M $43.03M $119.4M
YoY Change -73.42% -63.96% -9.06%
LONG-TERM ASSETS
Property, Plant & Equipment $1.336M $1.713M $2.000M
YoY Change -36.38% -14.35% 300.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $739.0K $732.0K $1.000M
YoY Change -26.1% -26.8% 0.0%
Total Long-Term Assets $2.203M $2.573M $3.000M
YoY Change -26.57% -14.23% 100.0%
TOTAL ASSETS
Total Short-Term Assets $27.28M $43.03M $119.4M
Total Long-Term Assets $2.203M $2.573M $3.000M
Total Assets $29.48M $45.60M $122.4M
YoY Change -72.09% -62.74% -7.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $891.0K $1.165M $1.500M
YoY Change -78.79% -22.33% -16.67%
Accrued Expenses $11.57M $18.97M $15.50M
YoY Change -30.7% 22.38% 154.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.36M $21.00M $17.80M
YoY Change -38.42% 17.96% 104.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.00K $2.576M $29.00M
YoY Change -99.92% -91.12% -27.5%
Total Long-Term Liabilities $20.00K $2.576M $29.00M
YoY Change -99.92% -91.12% -27.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.36M $21.00M $17.80M
Total Long-Term Liabilities $20.00K $2.576M $29.00M
Total Liabilities $25.85M $26.27M $46.70M
YoY Change -44.53% -43.75% -4.11%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $331.9M $330.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.631M $19.33M $75.60M
YoY Change
Total Liabilities & Shareholders Equity $29.48M $45.60M $122.4M
YoY Change -72.09% -62.74% -7.83%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$16.71M -$18.69M -$23.61M
YoY Change -6.23% -20.84% 120.19%
Depreciation, Depletion And Amortization $180.0K $200.0K $150.0K
YoY Change -10.0% 33.33% 150.0%
Cash From Operating Activities -$15.50M -$16.72M -$16.77M
YoY Change 5.44% -0.3% 188.14%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $10.00K $960.0K
YoY Change -100.0% -98.96% 500.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 -$10.00K -$960.0K
YoY Change -100.0% -98.96% 500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K 0.000 100.0K
YoY Change 900.0% -100.0% -99.18%
NET CHANGE
Cash From Operating Activities -15.50M -16.72M -16.77M
Cash From Investing Activities 0.000 -10.00K -960.0K
Cash From Financing Activities 200.0K 0.000 100.0K
Net Change In Cash -15.30M -16.73M -17.63M
YoY Change 1.66% -5.1% -382.08%
FREE CASH FLOW
Cash From Operating Activities -$15.50M -$16.72M -$16.77M
Capital Expenditures $0.00 $10.00K $960.0K
Free Cash Flow -$15.50M -$16.73M -$17.73M
YoY Change 2.85% -5.64% 196.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2006Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
5.09
CY2007Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
5.75
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83522763 shares
CY2005Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
3.93
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110391000
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83540682 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3406985 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.76
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6538419 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1430403 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
6481884 shares
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.85
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10441431 shares
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.85
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83540682 shares
CY2013Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2333000
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20997000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1165000
CY2013Q2 us-gaap Other Additional Capital
OtherAdditionalCapital
3728000
CY2013Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2576000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
19332000
CY2013Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
330735000
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18969000
CY2013Q2 us-gaap Liabilities
Liabilities
26271000
CY2013Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
365000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
84000
CY2013Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
63000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45603000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18864000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1509000
CY2012Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
6909000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12962000
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Expected Life
ClassOfWarrantOrRightFairValueAssumptionExpectedLife
5 Y
CY2009Q4 ziop Class Of Warrant Term
ClassOfWarrantTerm
P5Y
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Stock Volatility
ClassOfWarrantOrRightFairValueAssumptionStockVolatility
1.05 pure
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield
ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield
0.00 pure
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104713000
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
732000
CY2013Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1713000
CY2013Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
36709000
CY2013Q2 us-gaap Assets
Assets
45603000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38932000
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
956000
CY2013Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
315215000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
956000
CY2013Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6300000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
948000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4067000
CY2013Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
31000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
43030000
CY2013Q2 ziop Warrant Liabilities Fair Value Disclosure
WarrantLiabilitiesFairValueDisclosure
2576000
CY2009Q4 ziop Estimated Fair Value Of Warrant
EstimatedFairValueOfWarrant
22900000
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate
ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate
0.0214 pure
CY2012Q1 ziop Common Stock Price Per Share1
CommonStockPricePerShare1
5.20
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83236840 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3683786 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.11
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7147303 shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.56
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11197454 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83236840 shares
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2733000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
48445000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
325177000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16516000
CY2012Q4 us-gaap Liabilities
Liabilities
34959000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
400000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
83000
CY2012Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
39000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83404000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1001000
CY2012Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
133000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1994000
CY2012Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
72002000
CY2012Q4 us-gaap Assets
Assets
83404000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73306000
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3972000
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
283724000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6912000
CY2012Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
58000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
80276000
CY2012Q4 ziop Warrant Liabilities Fair Value Disclosure
WarrantLiabilitiesFairValueDisclosure
12962000
dei Trading Symbol
TradingSymbol
ZIOP
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M10D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1426400 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.49
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82994845 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.89
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34964000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y11D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
455168 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1580116 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17434175 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.87
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M27D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11D
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-4000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
115000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
10385000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
854000
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
us-gaap Interest Paid
InterestPaid
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2845000
us-gaap Contracts Revenue
ContractsRevenue
400000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-269000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
10385000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41879000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
250000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-27000
us-gaap Net Income Loss
NetIncomeLoss
-31491000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1673000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8392000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
705000
us-gaap Share Based Compensation
ShareBasedCompensation
1673000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
42279000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
250000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
396000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-34374000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-11000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-400000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
101000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2453000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-344000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
854000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-115000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33887000
ziop Milestone Payment Under License Agreement
MilestonePaymentUnderLicenseAgreement
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-6461000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41599000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-79000
us-gaap Net Income Loss
NetIncomeLoss
-48083000
ziop Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
101000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
425400 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77067424 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.48
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42625000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17695680 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
41000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1107000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-6461000
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
us-gaap Interest Paid
InterestPaid
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7738000
us-gaap Contracts Revenue
ContractsRevenue
400000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
53000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
412000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9750000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49410000
us-gaap Share Based Compensation
ShareBasedCompensation
2290000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
41999000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
265000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5678000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
172000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-400000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
210000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4681000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-258000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1107000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32249000
ziop Reclassification Of Warrant Liabilities To Equity
ReclassificationOfWarrantLiabilitiesToEquity
412000
ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
49170000
CY2006Q2 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2013-05-03
CY2006Q2 ziop Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
706708 shares
CY2007Q1 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2012-02-23
CY2007Q1 ziop Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
1359317 shares
CY2005Q2 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2012-05-31
CY2005Q2 ziop Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
579 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-256604000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
130000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4741000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
21156000
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-57000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4704000
us-gaap Interest Paid
InterestPaid
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4067000
us-gaap Contracts Revenue
ContractsRevenue
1867000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
732000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
21156000
us-gaap Operating Income Loss
OperatingIncomeLoss
-341075000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3117000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
31000
us-gaap Net Income Loss
NetIncomeLoss
-315215000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
352000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
96710000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
300276000
us-gaap Share Based Compensation
ShareBasedCompensation
21854000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
342942000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2970000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
38932000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
428000
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
500000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3133000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13180000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
18969000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1165000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2227000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4740000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
246232000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
16760000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
36151000
ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
270726000
ziop Issuance Of Warrants To Placement Agent In Public Offering
IssuanceOfWarrantsToPlacementAgentInPublicOffering
47276000
CY2009 ziop Warrants To Purchase Aggregate Shares Of Common Stock
WarrantsToPurchaseAggregateSharesOfCommonStock
8206520 shares
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M11D
CY2012 ziop Milestone Payment Under License Agreement
MilestonePaymentUnderLicenseAgreement
250000
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52600000
CY2012Q1 ziop Common Stock Shares Sold
CommonStockSharesSold
10114401 shares
CY2013Q2 ziop Number Of Employee Positions Eliminated
NumberOfEmployeePositionsEliminated
65 Position
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1315500 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0165 pure
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9545 pure
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83082633 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.77
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2013Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-403000
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2013Q2 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18296000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-18692000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3721000
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
132000
CY2013Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
18496000
CY2013Q2 us-gaap Severance Costs1
SeveranceCosts1
1600000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14775000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
361900 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8336 pure
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0110 pure
CY2012Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78514718 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.51
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4902000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0093 pure
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8352 pure
CY2012Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-650000
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2012Q2 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22966000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-23613000
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1078000
CY2012Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
23166000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18264000

Files In Submission

Name View Source Status
0001193125-13-326769-index-headers.html Edgar Link pending
0001193125-13-326769-index.html Edgar Link pending
0001193125-13-326769.txt Edgar Link pending
0001193125-13-326769-xbrl.zip Edgar Link pending
d558248d10q.htm Edgar Link pending
d558248dex311.htm Edgar Link pending
d558248dex312.htm Edgar Link pending
d558248dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20130630.xml Edgar Link completed
ziop-20130630.xsd Edgar Link pending
ziop-20130630_cal.xml Edgar Link unprocessable
ziop-20130630_def.xml Edgar Link unprocessable
ziop-20130630_lab.xml Edgar Link unprocessable
ziop-20130630_pre.xml Edgar Link unprocessable